https://orcid.org/0000-0002-1479-2737
References
- FDA. Table of surrogate endpoints that were the basis of drug approval or licensure; 2022. Available from: https://www.fda.gov/drugs/development-resources/table-surrogate-endpoints-were-basis-drug-approval-or-licensure
- Woods BS, Sideris E, Palmer S, et al. Partitioned survival and state transition models for healthcare decision making in oncology: where are we now? Value Health. 2020;23(12):1613–1621. doi: 10.1016/j.jval.2020.08.2094.
- Fitzmaurice C, Dicker D, Pain A, et al. The Global Burden of Cancer 2013. JAMA Oncol. 2015;1(4):505–527.
- Midha A, Dearden S, McCormack R. EGFR mutation incidence in non-small-cell lung cancer of adenocarcinoma histology: a systematic review and global map by ethnicity (mutMapII). Am J Cancer Res. 2015;5(9):2892–2911.
- Duma N, Santana-Davila R, Molina JR. Non-Small cell lung cancer: epidemiology, screening, diagnosis, and treatment. Mayo Clin Proc. 2019;94(8):1623–1640. doi: 10.1016/j.mayocp.2019.01.013.
- Bray F, Ferlay J, Soerjomataram I, et al. Global Cancer Statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424. doi: 10.3322/caac.21492.
- Goldstraw P, Chansky K, Crowley J, et al. The IASLC Lung Cancer Staging Project: proposals for revision of the TNM stage groupings in the forthcoming (eighth) edition of the TNM classification for lung cancer. J Thorac Oncol. 2016;11(1):39–51. doi: 10.1016/j.jtho.2015.09.009.
- Thandra KC, Barsouk A, Saginala K, et al. Epidemiology of lung cancer. Contemp Oncol. 2021;25(1):45–52.
- Blandin Knight S, Crosbie PA, Balata H, et al. Progress and prospects of early detection in lung cancer. Open Biol. 2017;7(9):170070. doi: 10.1098/rsob.170070.
- Chen Z, Fillmore CM, Hammerman PS, et al. Non-small-cell lung cancers: a heterogeneous set of diseases. Nat Rev Cancer. 2014;14(8):535–546. doi: 10.1038/nrc3775.
- Li Y, Appius A, Pattipaka T, et al. Real-world management of patients with epidermal growth factor receptor (EGFR) mutation-positive non-small-cell lung cancer in the USA. PLOS One. 2019;14(1):e0209709. doi: 10.1371/journal.pone.0209709.
- Holleman MS, van Tinteren H, Groen HJ, et al. First-line tyrosine kinase inhibitors in EGFR mutation-positive non-small-cell lung cancer: a network meta-analysis. Onco Targets Ther. 2019;12:1413–1421. doi: 10.2147/OTT.S189438.
- Li J, Kwok HF. Current strategies for treating NSCLC: from biological mechanisms to clinical treatment. Cancers. 2020;12(6):1587. doi: 10.3390/cancers12061587.
- Leonetti A, Sharma S, Minari R, et al. Resistance mechanisms to osimertinib in EGFR-mutated non-small cell lung cancer. Br J Cancer. 2019;121(9):725–737. doi: 10.1038/s41416-019-0573-8.
- Nakagawa K, Garon EB, Seto T, et al. Ramucirumab plus erlotinib in patients with untreated, EGFR-mutated, advanced non-small-cell lung cancer (RELAY): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2019;20(12):1655–1669. doi: 10.1016/S1470-2045(19)30634-5.
- EMA. Committee for Medicinal Products for Human Use/676031/2019. Summary of opinion (post authorisation); 2019. Available from: https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-cyramza-ii-33_en.pdf
- FDA. FDA approves ramucirumab plus erlotinib for first-line metastatic NSCLC; 2020. Available from: https://www.fda.gov/drugs/drug-approvals-and-databases/fda-approves-ramucirumab-plus-erlotinib-first-line-metastatic-nsclc
- NICE. Final appraisal document. Osimertinib for untreated EGFR mutation positive non-small-cell lung cancer; 2019. Available from: https://www.nice.org.uk/guidance/ta621/documents/final-appraisal-determination-document
- NICE. Single technology appraisal. Dacomitinib for untreated EGFR-positive non-small-cell lung cancer; 2019. Available from: https://www.nice.org.uk/guidance/ta595/evidence/appraisal-consultation-committee-papers-pdf-6894963614
- Haeussler K, Wang X, Winfree KB, et al. Efficacy and safety of first-line therapies in EGFR-mutated advanced non-small-cell lung cancer: a network meta-analysis. Future Oncol. 2022;18(16):2007–2028. doi: 10.2217/fon-2021-0885.
- Guyot P, Ades AE, Ouwens MJNM, et al. Enhanced secondary analysis of survival data: reconstructing the data from published Kaplan–Meier survival curves. BMC Med Res Methodol. 2012;12(1):9. doi: 10.1186/1471-2288-12-9.
- Fu H, Wang Y, Liu J, et al. Joint modeling of progression-free survival and overall survival by a Bayesian normal induced copula estimation model. Stat Med. 2013;32(2):240–254. doi: 10.1002/sim.5487.
- Fleischer F, Gaschler-Markefski B, Bluhmki E. A statistical model for the dependence between progression-free survival and overall survival. Stat Med. 2009;28(21):2669–2686. doi: 10.1002/sim.3637.
- Li Y, Zhang Q. A Weibull multi-state model for the dependence of progression-free survival and overall survival. Stat Med. 2015;34(17):2497–2513. doi: 10.1002/sim.6501.
- Miles DW, Chan A, Dirix LY, et al. Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer. J Clin Oncol. 2010;28(20):3239–3247. doi: 10.1200/JCO.2008.21.6457.